Kyrle Disease Treatment & Management
- Author: Daniel J Hogan, MD; Chief Editor: William D James, MD more...
Medical Care
Kyrle disease perhaps is most important as a cutaneous sign of a systemic disorder, although idiopathic cases without associated systemic disease occur. Therefore, direct therapeutic efforts toward any underlying condition. For patients in whom itching is a major problem, soothing antipruritic lotions containing menthol and camphor (Sarna) may be helpful. Sedating antihistamines such as hydroxyzine may be helpful for pruritus, especially at night. Potent topical corticosteroids such as Diprosone cream may help coexisting prurigo nodularis and lichen simplex chronicus.
UV light therapy is considered by some authorities to be the most effective treatment for acquired perforating dermatosis and is particularly helpful for patients with widespread lesions or coexisting pruritus from renal or hepatic disease.
Surgical Care
Carbon dioxide laser or cryosurgery may be helpful for limited lesions. Caution must be exercised for individuals with dark skin, especially with cryosurgery, and for lesions on the lower legs, particularly in patients with diabetes mellitus or poor circulation.
Consultations
Dermatologist or internal medicine specialist consultation may be necessary.
Carter VH, Constantine VS. Kyrle's disease. I. Clinical findings in five cases and review of literature. Arch Dermatol. Jun 1968;97(6):624-32. [Medline].
Constantine VS, Carter VH. Kyrle's disease. II. Histopathologic findings in five cases and review of the literature. Arch Dermatol. Jun 1968;97(6):633-9. [Medline].
Rapini RP, Herbert AA, Drucker CR. Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch Dermatol. Aug 1989;125(8):1074-8. [Medline].
White CR Jr, Heskel NS, Pokorny DJ. Perforating folliculitis of hemodialysis. Am J Dermatopathol. Apr 1982;4(2):109-16. [Medline].
Hurwitz RM, Melton ME, Creech FT 3rd, Weiss J, Handt A. Perforating folliculitis in association with hemodialysis. Am J Dermatopathol. Apr 1982;4(2):101-8. [Medline].
Alyahya GA, Heegaard S, Prause JU. Ocular changes in a case of Kyrle's disease. 20-year follow-up. Acta Ophthalmol Scand. Oct 2000;78(5):585-9. [Medline].
Kasiakou SK, Peppas G, Kapaskelis AM, Falagas ME. Regression of skin lesions of Kyrle's disease with clindamycin: implications for an infectious component in the etiology of the disease. J Infect. Jun 2005;50(5):412-6. [Medline].
Kahana M, Trau H, Dolev E, Schewach-Millet M, Gilon E. Perforating folliculitis in association with primary sclerosing cholangitis. Am J Dermatopathol. Jun 1985;7(3):271-6. [Medline].
Salomon RJ, Baden TJ, Gammon WR. Kyrle's disease and hepatic insufficiency. Arch Dermatol. Jan 1986;122(1):18-9. [Medline].
Khandpur S, Bansal A, Ramam M, et al. Verrucous tuberculid mimicking Kyrle disease. Int J Dermatol. Dec 2007;46(12):1298-301. [Medline].
Saleh HA, Lloyd KM, Fatteh S. Kyrle's disease. Effectively treated with isotretinoin. J Fla Med Assoc. Jun 1993;80(6):395-7. [Medline].
Bolognia JL, Rapini RP, Jorizzo JL, eds. Perforating Diseases. In: Dermatology. Vol 2. 2nd ed. St. Louis, Mo: Mosby; 2008:Chapter 95.
Price ML, Jones EW, MacDonald DM. Flegel's disease, not Kyrle's disease. J Am Acad Dermatol. Jun 1988;18(6):1366-7. [Medline].

